Full Text View
Tabular View
No Study Results Posted
Related Studies
A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)
This study has been completed.
First Received: December 22, 2001   Last Updated: June 23, 2005   History of Changes
Sponsor: GTx
Information provided by: GTx
ClinicalTrials.gov Identifier: NCT00028353
  Purpose

If you are a male 30 years of age or older and have a positive diagnosis of high grade (II or III) prostate Intraepithelial Neoplasia (PIN) or have had an abnormal/suspicious prostate biopsy, you may be eligible for this study. This is a study of an investigational medication that may reduce high grade PIN and prevent the occurrence of prostate cancer. This study is currently enrolling up to 500 men at approximately 60 locations in the United States.


Condition Intervention Phase
Prostatic Intraepithelial Neoplasia
Drug: GTX-006 (Acapodene)
Phase II

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:


Further study details as provided by GTx:

Estimated Enrollment: 500
Study Start Date: April 2001
Estimated Study Completion Date: July 2003
Detailed Description:

High grade PIN is the development of precancerous, abnormal tissue of the prostate gland that puts men at high risk of developing prostate cancer. This study will take one year of participation with clinic visits every three months. There will be two prostate biopsies during the study, at six and twelve months. If qualified to participate, you will be randomly assigned to one of four treatment groups. Three out of four groups are varying doses of the study medication and the other is the placebo group (like a sugar pill).

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
  • Must have confirmed high grade PIN on prostate biopsy within past 6 months.
  • Must have a serum PSA <12 ng/ml.
  • Can not have prostate cancer.
  • Have significant ocular opacities.
  • Can not take finasteride or other testosterone like supplement.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00028353

  Hide Study Locations
Locations
United States, Alabama
Private Practice
Huntsville, Alabama, United States, 35801
United States, Arkansas
Arkansas Urology Associates
Little Rock, Arkansas, United States, 72211
United States, Florida
UroSearch
Ocala, Florida, United States, 34474
The Urology Center of Florida Inc.
Ocala, Florida, United States, 34474
Dr. Byron Hodge
Orlando, Florida, United States, 32806
South Florida Medical Research
Aventura, Florida, United States, 33180
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612-9497
UroSearch
Leesburg, Florida, United States, 34748
United States, Georgia
Sandy Springs Urology, P.C.
Atlanta, Georgia, United States, 30328
United States, Idaho
North Idaho Urology
Couer D'Alene, Idaho, United States, 83814
United States, Indiana
Wishard Memorial Hospital
Indianapolis, Indiana, United States, 46202
United States, Maryland
Mid Atlantic Clinical Research
Rockville, Maryland, United States, 20850
United States, Massachusetts
Newton Wellesley Urology
Newton, Massachusetts, United States, 02162
United States, Nevada
Private Practice
Las Vegas, Nevada, United States, 89109
United States, New York
Clinical Research of Westchester
New Rochelle, New York, United States, 10801
Columbia University
New York, New York, United States, 10032
Private Practice
Staten Island, New York, United States, 10305
Medical & Clinical Research Associates
Bay Shore, New York, United States, 11706
United States, North Carolina
Salem Research Group, Inc.
Winston Salem, North Carolina, United States, 27103
United States, Ohio
Tri-State Urologic Services
Cincinnati, Ohio, United States, 45212
United States, Pennsylvania
Urologic Surgery, P.C
Bala Cynwyd, Pennsylvania, United States, 19004
Urology Associates of Lancaster
Lancaster, Pennsylvania, United States, 17604
United States, Texas
Urology San Antonio Research
San Antonio, Texas, United States, 78229
United States, Washington
Madigan Army Medical Center
Tacoma, Washington, United States, 98431
Seattle Urological Associates
Seattle, Washington, United States, 98104
Sponsors and Collaborators
GTx
  More Information

Additional Information:
No publications provided

Study ID Numbers: 211
Study First Received: December 22, 2001
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00028353     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by GTx:
PIN
High Grade Prostate Intraepithelial Neoplasia (PIN)

Additional relevant MeSH terms:
Prostatic Intraepithelial Neoplasia
Neoplasms
Neoplasms by Histologic Type
Carcinoma in Situ
Neoplasms, Glandular and Epithelial
Carcinoma

ClinicalTrials.gov processed this record on November 27, 2009